Senolytics (Dasatinib + Quercetin, Fisetin)

Verdict: Suggestive Last reviewed: 2026-04-24 Triangulated against anchor: NMN (Suggestive)

TL;DR

Senolytics are drugs that selectively kill senescent cells. The mouse evidence for healthspan benefit is genuine and replicated; the human evidence is early — small trials, surrogate endpoints, mixed signals from epigenetic clocks. Verdict: Suggestive, with real upside if larger human trials read positive.

What it is

A class of drugs that induce apoptosis in senescent ("zombie") cells, which accumulate with age and secrete pro-inflammatory factors (the senescence-associated secretory phenotype, SASP). The most-studied longevity-relevant agents:

• Dasatinib (D) — a tyrosine kinase inhibitor approved for chronic myeloid leukemia
• Quercetin (Q) — a flavonoid; commonly combined with D as "D+Q"
• Fisetin — a flavonoid, sometimes added to D+Q (DQF combinations) or used alone

Typical longevity dosing is intermittent (e.g., D+Q for 2 days every 2 weeks), based on the "hit and run" mechanism — kill senescent cells, then stop dosing. This is a critical distinction from chronic dosing protocols.

Proposed mechanism

Senescent cells resist apoptosis by upregulating "senescent cell anti-apoptotic pathways" (SCAPs). Dasatinib targets receptor tyrosine kinase-dependent SCAPs; quercetin/fisetin target Bcl-2 family / PI3K-dependent SCAPs. Combinations cover broader senescent-cell populations than either alone. Killing senescent cells reduces SASP burden, theoretically improving tissue function and healthspan.

Confidence: Plausible-to-Established for the mechanism in mice; Plausible for humans. The cellular biology is well-established. The leap to "killing senescent cells in vivo at achievable doses produces meaningful clinical benefit in humans" is plausible but not established.

Evidence ladder

Invertebrate (T5)

Senescence is mammalian-relevant; not a primary endpoint in invertebrate aging models. Some C. elegans data on related apoptotic pathways but not directly translatable.

Mouse / rat (T3-T4)

• Foundational work (Baker 2011, Nature; Baker 2016, Nature) — clearance of senescent cells via INK-ATTAC genetic model extended healthspan in mice. Gold-standard genetic evidence that senescent cells causally contribute to age-related dysfunction.
• D+Q in mice (Zhu 2015, Aging Cell; subsequent replications) — extended healthspan, improved frailty, restored function in multiple aged-mouse models. Replicated across labs.
• Fisetin in mice (Yousefzadeh 2018, EBioMedicine) — extended healthspan and median lifespan in late-life intervention. Single-lab; replication ongoing.
• ITP status: Senolytics have not been formally ITP-tested as solo lifespan interventions in the standard ITP protocol at time of writing. This is a meaningful gap — the strongest evidence pillar is missing.
• Effect size: Healthspan effects are robust; lifespan effects more modest and inconsistent.
• Replication: Multiple labs replicate healthspan effects of D+Q. Lifespan effects less consistently replicated.
• Sex / strain / dose: Heterogeneous. Mouse data uses both sexes and multiple strains, but pooled rigor is below ITP standards.

NHP (T4)

Limited. Some primate work on senolytic effects in specific tissues (skin, joints) but no NHP healthspan/lifespan data of comparable rigor.

Human (T2)

Multiple small early-phase trials, all surrogate endpoints:

• Justice et al. 2019 (EBioMedicine) — D+Q in idiopathic pulmonary fibrosis: feasibility/tolerability trial showed improved 6-minute walk, gait speed.
• Hickson et al. 2019 (EBioMedicine) — D+Q in diabetic kidney disease: reduced senescent cell markers in adipose biopsies.
• 2023 IPF trial (PubMed 36857968) — phase I single-blind randomized placebo-controlled pilot in IPF; established feasibility and tolerability.
• 2025 MCI / Alzheimer's risk trial — single-arm, n=12, D+Q intermittent dosing × 12 weeks; MoCA scores increased by 2.0 points; no serious adverse events. Promising but uncontrolled and small.
• DQF + epigenetic clocks (2024-2025) — Aging journal reports: first-generation clocks showed increased age acceleration after D+Q at 3 and 6 months, telomere length decreased, but second/third-generation clocks (more biologically anchored) showed no significant change. This is a confusing signal — a popular narrative ("senolytics reverse aging") is not what the cleanest clocks show in early human trials.
• Larger RCTs in progress — multiple registered trials in osteoarthritis, post-COVID, neurocognitive decline. Results pending.

Confounds

• Trial sizes are tiny (n=12 to n~50 in most published trials). Effect estimates are unstable.
• Surrogate endpoint selection — when first-gen clocks show acceleration but later-gen clocks don't, which is right? This is an active dispute and the popular discourse cherry-picks.
• "Hit and run" dosing complicates interpretation — short-term outcomes after one or two cycles may not reflect chronic effects.
• Open-label / single-arm designs dominate the published human literature.
• No mortality data, no large pre-registered RCT with hard endpoints.

Conflict of interest scan

• Mayo Clinic (Kirkland, Tchkonia) is the major academic origin — substantial NIA funding; some commercial spin-outs (Unity Biotechnology, others) — apply 1-tier discount on commercially-affiliated trials.
• Dasatinib is generic; minimal industry incentive to study it for off-label longevity at scale, which partly explains the small trial sizes.
• Net: most evidence is academically led; modest discount on commercially-tied human trials.

Human translation

The honest picture: senolytics are real biology with strong mouse evidence, and the human trials so far are small and consistent with "tolerable, possibly beneficial on some surrogates." The first-gen vs later-gen epigenetic clock divergence is a yellow flag, not a green or red one. The next 2-3 years of larger RCT readouts will clarify dramatically.

What senolytics are not: a proven anti-aging therapy. The popular framing — common in podcast and supplement marketing — significantly outruns the evidence.

Calibrated verdict

Suggestive. The bar is "T3 or T4 evidence with replication, but human data absent or null/early." Senolytics fit: T3-T4 mouse evidence well-replicated for healthspan, lifespan signal weaker, human data is early and mixed.

Compared to NMN (Suggestive), senolytics have better mechanistic foundation (genetic causal evidence via INK-ATTAC mice — NMN has nothing comparable) and cleaner mouse healthspan data, but less human RCT volume to date. They sit at roughly the same band but for opposite reasons: NMN has more human trials of weaker studies; senolytics have stronger preclinical and earlier human evidence.

Compared to rapamycin (Probable), senolytics lack ITP testing — the single most decisive piece of evidence rapamycin has. That gap keeps senolytics one band below.

Confidence interval on verdict

• Could move to Probable if (a) a pre-registered, placebo-controlled D+Q or fisetin trial with hard or near-hard endpoints (e.g., functional decline, frailty) reports positive at n>200, OR (b) ITP tests senolytics and reports positive lifespan data. Both plausible within 2-3 years.
• Could move to Mostly hype if the larger RCTs in progress read consistently null and the first-gen clock acceleration signal proves to be a real biological effect rather than a measurement artifact.
• Most likely 2-year trajectory: stays at Suggestive; lean toward upgrade.

Open questions

• Q: Has the ITP committed to testing D+Q, fisetin, or other senolytics? Status?
• Q: How do we interpret the first-gen vs later-gen epigenetic clock divergence in human D+Q trials? Is this "the first-gen clocks are noise" or "the senolytics genuinely accelerate something the first-gen clocks measure"?
• Q: What is the optimal human dosing schedule? Cycles per year, dose magnitude — these are still empirical.
• Q: Do fisetin's claimed benefits hold up in adequately-powered human trials, or is fisetin enthusiasm running ahead of data?
• Q: Are there senescent-cell-population-specific senolytics emerging (e.g., Bcl-xL-targeted Unity drugs) that change the picture?

Sources

• Baker et al. 2011, Nature — Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
• Baker et al. 2016, Nature — Naturally occurring p16Ink4a-positive cells shorten healthy lifespan
• Zhu et al. 2015, Aging Cell — The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
• Yousefzadeh et al. 2018, EBioMedicine — Fisetin is a senotherapeutic that extends health and lifespan
• Justice et al. 2019, EBioMedicine — D+Q in IPF feasibility trial
• Hickson et al. 2019, EBioMedicine — D+Q in diabetic kidney disease
• 2023 IPF phase I RCT, PubMed 36857968
• 2025 MCI single-arm trial summary
• Aging journal — DQF longitudinal study on epigenetic clocks
• NCT04313634 — Targeting Cellular Senescence With Senolytics

Produced under methodology locked 2026-04-24. Triangulated against NMN anchor.